News & Perspective

Mar 01, 2012

Mar 01, 2012

FDA clears first quadrivalent flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product.

The vaccine includes a second influenza B strain, which is designed to broaden protection against circulating strains. MedImmune plans to have the quadrivalent vaccine ready for the 2013-14 flu season.

Mar 01, 2012

Another study shows limited flu vaccine benefits in seniors

(CIDRAP News) – A study published this week adds another to a short list of recent investigations suggesting that standard influenza vaccines yield only modest reductions in the risk of hospitalization or death in elderly people.

Mar 02, 2012

Mar 02, 2012

US flu markers show steady rise

(CIDRAP News) – Flu activity in the United States showed a moderate spike last week, with a jump in states reporting widespread activity, the US Centers for Disease Control and Prevention (CDC) reported today.

The number of respiratory specimens testing positive for flu, another marker of flu activity, also showed a steady rise last week, increasing to 18.4%, compared with 14.4% the week before.

Mar 05, 2012

Mar 05, 2012

Report cites mixed data on resistant bacteria in poultry, meat

(CIDRAP News) – A new US government report shows that the prevalence of antibiotic-resistant bacteria in retail poultry and meat samples in 2010 varied greatly depending on the type of bacteria and meat, with resistant Salmonella in chicken breasts one of the more common findings.

Mar 05, 2012

Vietnam, Bangladesh report more H5N1 cases

(CIDRAP News) – The World Health Organization (WHO) today reported another human H5N1 avian influenza illness in Vietnam, while an online newspaper reported two more cases in poultry market workers in Bangladesh.

Mar 05, 2012

Details of H5N1 study spark queries from congressman, experts

(CIDRAP News) – A US congressman has stepped into the debate over two controversial H5N1 transmission studies, asking President Obama's science office why a federal advisory board didn't consider dual-use issues until after the experiments were completed and what safeguards are in place.

Pages

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»